Healthcare

Basal media, fetal bovine media, and balanced salt solutions are prevalent cell culture media. However, serum free media and growth, as well as attachment factors, are expected to see increased use in 2013 because current non-users are planning to include them in their workflow. Overall, Asia-Pacific is still a growing market in terms of the numbe...

This is a repackaging of this research deliverable. During the fourth quarter of 2009, Frost & Sullivan conducted a Customer Research project titled Medical Imaging IT Middleware: A Study of Customer Perceptions and Purchase Intentions in the U.S. Hospital Market. The study aimed to provide the vendors developing, selling, and implementing medical ...

This issue of Vital Signs, released on April 30, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Life Sciences and Advanced Medical Technology.

This research service analyzes the US general X-ray radiography imaging equipment market, which is transitioning toward more compact portable and modular digital technologies. The market segments evaluated are analog radiography, computed radiography (CR), and digital radiography (DR). The suites, mobiles, and retrofits sub-segments of the DR segme...

This research service pertains to the US market for interventional x-ray equipment used in radiology and cardiology. A thorough market sizing and forecasting model of market revenue, unit shipments, and pricing is included, along with analyses of technology trends, market drivers and restraints, and the competitive environment. The two market segme...

This research service evaluates the U.S. qPCR reagents market from 2010 to 2017. The mature qPCR reagents market remains dynamic due to a period of patent expirations, competitive expansion, and pricing pressure. This research service offers a discussion of the key market drivers and restraints, a detailed analysis of the changing competitive lands...

This issue of Vital Signs, released on March 28, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Life Sciences and Advanced Medical Technology.

This issue of Vital Signs, released on March 7, 2013, provides an insight in to battle between FDA and branded and generic pharmaceutical companies. Additionally, a company spotlight is provided for PLC Diagnostics. PLC Diagnostics is an early stage startup, developing the next generation of handheld point-of-care testing devices.

Breakthroughs in drug discovery have led to rich and competitive pipelines for rare diseases such as rare cancers as well as neurologic disorders and musculoskeletal disorders, among many other therapeutic areas. This research service provides a comprehensive global overview and analysis of global orphan drugs development, with an emphasis on the U...